{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".368","upperLimit":".618","value":".5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"}],"units":"Participants"}],"description":"This hypothesis will be rejected if the 95% confidence interval for year DFS rate computed from the estimated Kaplan-Meier survival curves will be entirely above 0.35.","dispersionType":"95% Confidence Interval","groups":[{"description":"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -15 to -12, busulfan IV on days -14 to -13, DLI on day -6, and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI on day -10.\n\nTRANSPLANT: Patients undergo allogeneic PBSCT on day 0.\n\nGVHD PROPHYLAXIS: Patients receive tacrolimus IV on days -1 to 42 followed by taper and mycophenolate mofetil IV BID on days -1 to 28\n\nFludarabine phosphate: Given IV\n\nBusulfan: Given IV\n\nTotal-Body Irradiation: Undergo TBI\n\nTherapeutic Allogeneic Lymphocytes: Undergo DLI\n\nCyclophosphamide: Given IV\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSCT\n\nPeripheral Blood Stem Cell Transplantation: Undergo allogeneic PBSCT\n\nTacrolimus: Given IV\n\nMycophenolate Mofetil: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Treatment (RIC and allogeneic PBSCT)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year post hematopoietic stem cell transplant (HSCT)","title":"Disease-free Survival (DFS)","type":"PRIMARY","unitOfMeasure":"proportion of participants"}